Mechanism of Action.
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), retaining the anti-inflammatory activity of the parent hormone without its melanogenic (tanning) effects. KPV enters cells and directly inhibits the NF-kB inflammatory signaling cascade by interfering with IKK-beta activation, preventing nuclear translocation of NF-kB and subsequent pro-inflammatory gene transcription. This reduces production of TNF-alpha, IL-1beta, IL-6, and other inflammatory mediators. Additionally, KPV interacts with melanocortin receptors (primarily MC1R and MC3R) on immune cells, modulating macrophage and neutrophil inflammatory responses. In gut tissue, KPV reduces epithelial permeability, supports mucosal barrier integrity, and decreases inflammatory cell infiltration.
Research Summary.
KPV research has focused heavily on inflammatory bowel conditions. In animal models of colitis, KPV administration (including oral delivery) significantly reduced inflammatory scores, decreased cytokine levels, and promoted mucosal healing. A key finding is that KPV retains anti-inflammatory potency when administered orally, as the small tripeptide can survive gastric digestion and act on colonic epithelial cells directly. Studies also demonstrate KPV efficacy in skin inflammation models, reducing contact dermatitis and allergic inflammation. Research into KPV-loaded nanoparticles for targeted colonic delivery has shown promising results for inflammatory bowel disease applications. The anti-inflammatory effects are broad-spectrum, acting on multiple cell types and inflammatory pathways simultaneously.
Side Effects & Safety.
KPV has demonstrated a very favorable safety profile in preclinical research. As a naturally occurring fragment of alpha-MSH, it is endogenous and well-tolerated. Unlike full-length alpha-MSH, KPV does not produce melanogenic effects (skin darkening) or significant effects on appetite and energy balance at anti-inflammatory doses. No significant adverse effects have been reported in animal studies. Human clinical trial data is limited, so the complete safety profile has not been formally established. The small size and rapid metabolism of KPV suggest minimal accumulation risk.
Legal Status & Access.
KPV is classified as a Category 1 research peptide. It is not FDA-approved for any clinical indication. Available from research peptide suppliers for laboratory investigation.